Condor Capital Management Has $4.31 Million Holdings in Novo Nordisk A/S $NVO

Condor Capital Management lifted its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 2.8% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 62,402 shares of the company’s stock after purchasing an additional 1,728 shares during the quarter. Condor Capital Management’s holdings in Novo Nordisk A/S were worth $4,307,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Stone House Investment Management LLC acquired a new stake in Novo Nordisk A/S during the first quarter worth approximately $30,000. NewSquare Capital LLC lifted its position in shares of Novo Nordisk A/S by 174.1% during the 2nd quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock valued at $31,000 after acquiring an additional 282 shares during the period. Disciplina Capital Management LLC grew its holdings in shares of Novo Nordisk A/S by 162.3% during the 1st quarter. Disciplina Capital Management LLC now owns 480 shares of the company’s stock worth $33,000 after purchasing an additional 297 shares in the last quarter. Dagco Inc. bought a new position in shares of Novo Nordisk A/S in the first quarter worth $35,000. Finally, Mid American Wealth Advisory Group Inc. bought a new position in shares of Novo Nordisk A/S in the second quarter worth $37,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Price Performance

NVO stock opened at $48.22 on Friday. The stock has a market cap of $215.32 billion, a price-to-earnings ratio of 13.25, a P/E/G ratio of 2.33 and a beta of 0.65. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.56. The company has a 50 day simple moving average of $54.55 and a 200 day simple moving average of $61.04. Novo Nordisk A/S has a 1 year low of $45.05 and a 1 year high of $112.52.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.77 by $0.25. The company had revenue of $11.74 billion during the quarter, compared to the consensus estimate of $11.98 billion. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. Novo Nordisk A/S has set its FY 2025 guidance at EPS. Research analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on NVO shares. Jefferies Financial Group assumed coverage on shares of Novo Nordisk A/S in a research note on Monday, October 27th. They set an “underperform” rating on the stock. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a research report on Tuesday, September 9th. Weiss Ratings restated a “sell (d+)” rating on shares of Novo Nordisk A/S in a research report on Tuesday. Berenberg Bank upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Wednesday, September 17th. Finally, BNP Paribas upgraded Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a research note on Wednesday, August 13th. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, nine have given a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat, Novo Nordisk A/S presently has a consensus rating of “Hold” and a consensus target price of $59.20.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.